Tucker GT - Search Results

1

Sensitivity of indirect metrics for assessing "rate" in bioequivalence studies--moving the "goalposts" or changing the "game".

Rostami-Hodjegan A, Jackson PR, Tucker GT. Rostami-Hodjegan A, et al. Among authors: tucker gt. J Pharm Sci. 1994 Nov;83(11):1554-7. doi: 10.1002/jps.2600831107. J Pharm Sci. 1994. PMID: 7891273

2

The effects of dose staggering on metabolic drug-drug interactions.

Yang J, Kjellsson M, Rostami-Hodjegan A, Tucker GT. Yang J, et al. Among authors: tucker gt. Eur J Pharm Sci. 2003 Oct;20(2):223-32. doi: 10.1016/s0928-0987(03)00200-8. Eur J Pharm Sci. 2003. PMID: 14550889

3

Prediction of plasma protein binding displacement and its implications for quantitative assessment of metabolic drug-drug interactions from in vitro data.

Christensen H, Baker M, Tucker GT, Rostami-Hodjegan A. Christensen H, et al. Among authors: tucker gt. J Pharm Sci. 2006 Dec;95(12):2778-87. doi: 10.1002/jps.20733. J Pharm Sci. 2006. PMID: 16937340

4

Is Cmax/AUC useful for bioequivalence testing?

Rostami-Hodjegan A, Tucker GT. Rostami-Hodjegan A, et al. Among authors: tucker gt. J Pharm Sci. 1997 Dec;86(12):1504-5. doi: 10.1021/js970153t. J Pharm Sci. 1997. PMID: 9423170 No abstract available.

5

The absorption kinetics of ketoconazole plays a major role in explaining the reported variability in the level of interaction with midazolam: Interplay between formulation and inhibition of gut wall and liver metabolism.

Liu B, Crewe HK, Ozdemir M, Rowland Yeo K, Tucker G, Rostami-Hodjegan A. Liu B, et al. Biopharm Drug Dispos. 2017 Apr;38(3):260-270. doi: 10.1002/bdd.2058. Epub 2017 Feb 14. Biopharm Drug Dispos. 2017. PMID: 28004396

6

Kinetic values for mechanism-based enzyme inhibition: assessing the bias introduced by the conventional experimental protocol.

Yang J, Jamei M, Yeo KR, Tucker GT, Rostami-Hodjegan A. Yang J, et al. Among authors: tucker gt. Eur J Pharm Sci. 2005 Nov;26(3-4):334-40. doi: 10.1016/j.ejps.2005.07.005. Eur J Pharm Sci. 2005. PMID: 16137870

7

Simulation and prediction of in vivo drug metabolism in human populations from in vitro data.

Rostami-Hodjegan A, Tucker GT. Rostami-Hodjegan A, et al. Among authors: tucker gt. Nat Rev Drug Discov. 2007 Feb;6(2):140-8. doi: 10.1038/nrd2173. Nat Rev Drug Discov. 2007. PMID: 17268485 Review.

8

The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies -CYP2C9 and warfarin as an example.

Dickinson GL, Lennard MS, Tucker GT, Rostami-Hodjegan A. Dickinson GL, et al. Among authors: tucker gt. Br J Clin Pharmacol. 2007 Jul;64(1):14-26. doi: 10.1111/j.1365-2125.2007.02850.x. Epub 2007 Feb 12. Br J Clin Pharmacol. 2007. PMID: 17298479 Free PMC article.

9

Theoretical assessment of a new experimental protocol for determining kinetic values describing mechanism (time)-based enzyme inhibition.

Yang J, Jamei M, Yeo KR, Tucker GT, Rostami-Hodjegan A. Yang J, et al. Among authors: tucker gt. Eur J Pharm Sci. 2007 Jul;31(3-4):232-41. doi: 10.1016/j.ejps.2007.04.005. Epub 2007 Apr 25. Eur J Pharm Sci. 2007. PMID: 17512176

10

Inactivation of CYP2D6 by methylenedioxymethamphetamine in different recombinant expression systems.

Van LM, Hargreaves JA, Lennard MS, Tucker GT, Rostami-Hodjegan A. Van LM, et al. Among authors: tucker gt. Eur J Pharm Sci. 2007 Sep;32(1):8-16. doi: 10.1016/j.ejps.2007.05.002. Epub 2007 May 22. Eur J Pharm Sci. 2007. PMID: 17574396

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

305 results

Search Page

Filters